Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2012
03/21/2012CN101555469B High-efficiency recombined adenovirus containing ndrg2 gene and pharmic purpose thereof
03/21/2012CN101555283B Antibodies to non-functional p2x7 receptor, diagnosis and treatment of cancers and other conditions
03/21/2012CN101443002B Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
03/21/2012CN101375937B Cudrania tricuspidata extract, preparation and application thereof
03/21/2012CN101352477B Use of ormosia seed extract in preparing anti-tumor medicament
03/21/2012CN101343331B Synthesis of substituted pachyman
03/21/2012CN101310717B preparation method of tanshinone IIA polylactic acid nano particles
03/21/2012CN101298427B Diaryl urea compound and use thereof
03/21/2012CN101297966B Tumor vaccine for intestinal cancer containing rich chaperone-antigenic peptide complexes and preparation thereof
03/21/2012CN101249082B Preparation of acidum citricum tamoxifen polylactic acid-glycolic co-polymer microballoons
03/21/2012CN101181225B System for transferring nanometer polyalcohol micelle medicament and preparing method as well as application thereof
03/21/2012CN101035795B Thiazolyl-dihydro indazoles
03/21/2012CN101007803B Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
03/20/2012US8138353 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
03/20/2012US8138337 Reverse-turn mimetics and method relating thereto
03/20/2012US8138336 Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
03/20/2012US8138314 Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations
03/20/2012US8138311 Modified proteins, designer toxins, and methods of making thereof
03/20/2012US8138310 Chimeric CD154 polypeptides
03/20/2012US8138202 Stable SNS-595 compositions and methods of preparation
03/20/2012US8138200 Compositions and methods for double-targeting virus infections and targeting cancer cells
03/20/2012US8138195 Inhibitors of human phosphatidylinositol 3-kinase delta
03/20/2012US8138181 Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
03/20/2012US8138159 Composition for inhibiting function of human Flt3
03/20/2012US8137932 Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragment
03/20/2012US8137915 Genes involved in intestinal inflammatory diseases and use thereof
03/20/2012US8137689 Transplant/implant device and method for its production
03/20/2012US8137663 Oncolytic virus therapy
03/20/2012US8137662 Proliferated cell lines and uses thereof
03/20/2012CA2656507C Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
03/20/2012CA2628131C Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
03/20/2012CA2553423C Heterocyclic compounds for use in the treatment of cancer and the inhibition of angiogenesis
03/20/2012CA2518115C Nucleotide phosphoramidates as anticancer agents
03/20/2012CA2513583C Modified retinoid compounds and their uses
03/20/2012CA2474688C Improved process for obtaining betulinic acid
03/20/2012CA2466099C Composition containing feverfew extract and use thereof
03/20/2012CA2462227C Adhesive antineoplastic compositions
03/20/2012CA2455455C Method and system to determine revised dosage
03/20/2012CA2453510C Treatment of fatigue and cognitive side effects associated with cancer, cancer treatments and menopause with d-threo-methyphenidate
03/20/2012CA2446872C Immune-modulating peptide
03/20/2012CA2435683C Hybridoma cell line g250 and its use for producing monoclonal antibodies
03/20/2012CA2424359C Implants with a phosphazene-containing coating
03/20/2012CA2410901C Methods and compounds for controlled release of recombinant parvovirus vectors
03/20/2012CA2405469C Integrin binding peptide derivatives
03/20/2012CA2402719C Method of preparing alkylated salicylamides via a dicarboxylate intermediate
03/20/2012CA2396227C 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation
03/20/2012CA2392453C Modulation of signal transduction
03/20/2012CA2363067C Compounds and methods to inhibit or augment an inflammatory response
03/20/2012CA2351580C Stabilization of macrolides
03/20/2012CA2299560C Human defensin def-x, gene and dnac, composition containing same and diagnostic and therapeutic applications
03/20/2012CA2296842C Ligands, including antibodies, showing reactivity against endocrine cells
03/15/2012WO2012034132A2 Inhibitors of human ezh2, and methods of use thereof
03/15/2012WO2012034116A2 Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
03/15/2012WO2012034095A1 Compounds and compositions as trk inhibitors
03/15/2012WO2012034079A2 Macrolide dosage forms
03/15/2012WO2012034055A2 Compounds as c-met kinase inhibitors
03/15/2012WO2012033987A2 Anti-human folate receptor beta antibodies and methods of use
03/15/2012WO2012033901A2 Somatostatin receptor-based cancer therapy
03/15/2012WO2012033601A1 Thiosemicarbazones with mdr1 - inverse activity
03/15/2012WO2012033525A2 P53-mdm2 antagonists
03/15/2012WO2012033266A1 Novel artemisinin or deoxoartemisinin-glycolipid hybrid derivatives and antiangiogenic use thereof
03/15/2012WO2012033016A1 Drug for treating tumor, antitumor agent, method for treating tumor and kit for treating tumor
03/15/2012WO2012032764A1 Ttll4 peptides and vaccines containing the same
03/15/2012WO2012032763A1 Vangl1 peptides and vaccines including the same
03/15/2012WO2012032524A1 Near infrared fluorescent particles and uses thereof
03/15/2012WO2012032433A1 4-1bb binding molecules
03/15/2012WO2012032143A1 Phosphorylated twist1 and metastasis
03/15/2012WO2012032031A1 Substituted imidazopyridazines
03/15/2012WO2012031773A1 Sdf-1 binding nucleic acids and the use thereof in cancer treatment
03/15/2012WO2012031609A1 Biodegradable, water soluble and ph responsive poly(organo)phosphazenes
03/15/2012WO2012031603A2 Airway administration of angiogenesis inhibitors
03/15/2012WO2012031563A1 Heterocyclic amino berbamine derivatives, preparation method and use thereof
03/15/2012WO2012031539A1 Nucleoside derivatives, synthesis methods and uses thereof for preparing anti-tumor and anti-virus medicaments
03/15/2012WO2012031457A1 A medicine delayed release vascular embolization gel used for treating tumor and preparation process thereof
03/15/2012WO2012031333A1 Companion animal treatments
03/15/2012WO2011163430A9 Polymorphs of osi-906
03/15/2012WO2011150897A3 Cancer therapy method
03/15/2012WO2011147982A3 Monoclonal antibodies against her2 epitope
03/15/2012WO2011146828A3 Cancer treatment
03/15/2012WO2011146589A8 Vitamin e conjugates, and their uses as antioxidants and prodrug delivery vehicles
03/15/2012WO2011139868A3 Method for treating esophageal cancer
03/15/2012WO2011133773A3 Compositions and methods for leukocyte-targeting multi-valent imaging probes
03/15/2012WO2011133659A3 Inhibitors of hif and angiogenesis
03/15/2012WO2011130611A3 Treating disorders associated with il-20 receptor-mediated signaling pathway by blocking il-20 receptor activity
03/15/2012WO2011127465A3 Ship inhibitors and uses thereof
03/15/2012WO2011121317A9 Imidazothiadiazoles for use as kinase inhibitors
03/15/2012WO2011118981A9 Novel use of erythroid differentiation regulator 1 as an agent for treating cancer
03/15/2012WO2011078394A3 Sustained-release formulation
03/15/2012WO2002033044A9 Methods of high-throughput screening for internalizing antibodies
03/15/2012US20120065620 Bone marrow extracellular matrix extract and therapeutic use thereof
03/15/2012US20120065614 Polyionic transitional metal phosphorescent complex/polymer hybrid systems for bioimaging and sensing applications
03/15/2012US20120065385 Dendritic cell co-stimulatory molecules
03/15/2012US20120065380 Dual targeting antibody of novel form, and use thereof
03/15/2012US20120065374 Dendritic cell co-stimulatory molecules
03/15/2012US20120065368 Cyclodextrin-based polymers for therapeutics delivery
03/15/2012US20120065270 Potassium ion channel modulators and uses thereof
03/15/2012US20120065255 Cabazitaxel formulations and methods of preparing thereof
03/15/2012US20120065251 Mir-21 promoter driven targeted cancer therapy
03/15/2012US20120065248 Methods and compositions involving mirna and mirna inhibitor molecules
03/15/2012US20120065247 Modulating ires-mediated translation
1 ... 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 ... 2211